ReviewBioMed research international2013
Update on anticytokine treatment for asthma.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Effect of Src tyrosine kinase on a rat model of asthma.Experimental and therapeutic medicine · 2022Article
- Targeting TSLP in Asthma.Journal of asthma and allergy · 2022Review
- Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control.BioMed research international · 2021Review
- Sevoflurane modulates AQPs (1,5) expression and endoplasmic reticulum stress in mice lung with allergic airway inflammation.Bioscience reports · 2019Article
- HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.The Journal of clinical investigation · 2019Article
- Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.BioMed research international · 2018Review
- Potential new targets for drug development in severe asthma.The World Allergy Organization journal · 2018Review
- Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.Drug design, development and therapy · 2018Review
- Review
- Osthole treatment ameliorates Th2-mediated allergic asthma and exerts immunomodulatory effects on dendritic cell maturation and function.Cellular & molecular immunology · 2017Article
- Somatic extracts of Marshallagia marshalli downregulate the Th2 associated immune responses in ovalbumin-induced airway inflammation in BALB/c mice.Parasites & vectors · 2017Article
- Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug design, development and therapy · 2017Review
- From IgE to Omalizumab.Journal of immunology (Baltimore, Md. : 1950) · 2016Review
- Prenatal diagnosis, 3-D virtual rendering and lung sparing surgery by ligasure device in a baby with "CCAM and intralobar pulmonary sequestration".Open medicine (Warsaw, Poland) · 2016Article
- Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma.Open medicine (Warsaw, Poland) · 2016Article
- Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer.Open medicine (Warsaw, Poland) · 2016Article
- Role of biologics in severe eosinophilic asthma - focus on reslizumab.Therapeutics and clinical risk management · 2016Review
- Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia.Open medicine (Warsaw, Poland) · 2016Article
- Cushing's like syndrome in typical bronchial carcinoid a case report and review of the literature.International journal of surgery case reports · 2016Article
- Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge.BMC pulmonary medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current advances in the knowledge of asthma pathobiology suggest that anticytokine therapies can be potentially useful for the treatment of this complex and heterogeneous airway disease. Recent evidence is accumulating in support of the efficacy of anti-IL-4, anti-IL-5, and anti-IL-13 drugs. Therefore, these new developments are now changing the global scenario of antiasthma therapies, especially with regard to more severe disease. Current findings referring to variability of individual therapeutic responses highlight that the different asthma subtypes need to be well characterized, in order to implement phenotype-targeted treatments which in the near future will hopefully be mainly based on cytokine-directed biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.